Discovering Pathways for Novel Antimicrobial Polyketides

Information

  • Research Project
  • 6790253
  • ApplicationId
    6790253
  • Core Project Number
    R44AI052585
  • Full Project Number
    2R44AI052585-02
  • Serial Number
    52585
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/10/2002 - 23 years ago
  • Project End Date
    12/31/2004 - 20 years ago
  • Program Officer Name
    KORPELA, JUKKA K.
  • Budget Start Date
    4/1/2004 - 21 years ago
  • Budget End Date
    12/31/2004 - 20 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    3/22/2004 - 21 years ago
Organizations

Discovering Pathways for Novel Antimicrobial Polyketides

[unreadable] DESCRIPTION (provided by applicant): Polyketides are a large group of important bioactive compounds that include many anti-microbial agents. Most bioactive polyketides of microbial origin are made by actinomycetes, which are high GC Gram-positive bacteria frequenting both terrestrial and marine environments. Genes dedicated to the synthesis of a particular Type II polyketide are invariably clustered on the actinomycete chromosome and undoubtedly share a common evolutionary origin. In order to discover novel polyketide biosynthetic pathways from the majority of uncultured microorganisms present in the environment, all of Diversa's large insert fosmid libraries will be screened for Type II polyketide synthase genes using the large insert FACS biopanning technology developed in Phase I. Diversa's fosmid library collection will cover approximately 13950 genomes. Putative polyketide pathways will be transferred to our proprietary expression host Streptomyces diversa and extracts from the resulting clones will be analyzed for anti-microbial activity. Extracts of active clones will be chemically characterized and the corresponding fosmids will be sequenced to identify pathways that encode potentially novel compounds. S. diversa clones apparently producing new anti-microbial polyketides will be used to produce sufficient quantities of the compounds for further pre-clinical analysis (e.g. range of activity, toxicity, and mechanism of action). [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    371684
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:371684\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DIVERSA CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921213829
  • Organization District
    UNITED STATES